SCHEMBL10067276

SCHEMBL10067276

O=C(Cn1cc(-c2nc3c4cccnc4c4ncccc4c3[nH]2)c2ccccc21)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALDH1A1 P00352 5/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
HTT P42858 1/20 0.47
TP53 P04637 6/20 0.47
LMNA P02545 2/20 0.47
CASP3 P42574 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 2/20 0.47
POLB P06746 2/20 0.47
GAA P10253 1/20 0.47
SENP8 Q96LD8 1/20 0.47
ATM Q13315 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067267 0.92 MAPT (0.46) MAPTALDH1A1TP53LMNAGAA
SCHEMBL10067272 0.91 MAPT (0.48) MAPTALDH1A1TP53LMNAPOLB
SCHEMBL10067302 0.91 MAPT (0.48) MAPTALDH1A1TP53LMNAPOLB
SCHEMBL10067310 0.89 KMT2A (0.48) KMT2AMEN1MAPTHTTTP53
SCHEMBL10067293 0.88 ALDH1A1 (0.52) KMT2AMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL10067286 0.83 KMT2A (0.42) KMT2AMEN1MAPTALDH1A1NPC1
SCHEMBL10067280 0.82 IDO1 (0.47) KMT2AMEN1MAPTALDH1A1TP53
SCHEMBL10067292 0.80 MAPT (0.52) KMT2AMEN1MAPTSMN1; SMN2CYP3A4
SCHEMBL10067264 0.75 PDE4A (0.45) KMT2AMEN1SMN1; SMN2ALDH1A1TDP1
SCHEMBL10067277 0.72 LMNA (0.50) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 KMT2A 377/4885MEN1 2366/4885MAPT 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.